|
業務類別
|
Biotechnology |
|
業務概覽
|
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents. |
| 公司地址
| 700 Saginaw Drive, Redwood City, CA, USA, 94063 |
| 電話號碼
| +1 650 481-6801 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.revmed.com |
| 員工數量
| 883 |
| Mr. Jack Anders |
Chief Financial Officer and Principal Accounting Officer |
美元 523.33K |
27/04/2026 |
| Dr. Mark A. Goldsmith, M.D., PhD |
President, Chief Executive Officer and Chairman of the Board |
美元 812.50K |
27/04/2026 |
| Dr. Stephen M. Kelsey, F.R.C.P.,M.D. |
President, Research and Development |
美元 625.83K |
27/04/2026 |
| Ms. Margaret A. Horn, J.D. |
Chief Operating Officer |
美元 582.67K |
27/04/2026 |
| Mr. Jeffrey Cislini |
Senior Vice President, General Counsel and Secretary |
美元 523.75K |
27/04/2026 |
| Dr. Alan B. Sandler, M.D. |
Chief Development Officer |
-- |
27/04/2026 |
| Mr. Anthony Mancini |
Chief Global Commercialization Officer |
-- |
27/04/2026 |
|
|
| Dr. Sushil Patel, PhD |
Independent Director |
27/04/2026 |
| Ms. Elizabeth McKee Anderson, M.B.A. |
Independent Director |
27/04/2026 |
| Dr. Mark A. Goldsmith, M.D., PhD |
President, Chief Executive Officer and Chairman of the Board |
27/04/2026 |
| Dr. Lorence H. Kim, M.D. |
Independent Director |
27/04/2026 |
| Dr. Thilo Schroeder, PhD |
Independent Director |
27/04/2026 |
| Mr. Frank K. Clyburn, Jr |
Independent Director |
27/04/2026 |
| Mr. Alexis A. Borisy, A.M. |
Lead Independent Director |
27/04/2026 |
| Dr. Sandra J. Horning, M.D. |
Independent Director |
27/04/2026 |
| Dr. Flavia Borellini, PhD |
Independent Director |
27/04/2026 |
|
|
|
|
